Carmot Therapeutics initiated a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors.
The phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of CT-868 in overweight or obese but otherwise healthy volunteers and patients with type 2 diabetes, according to a company release.
“The therapeutic benefits of simultaneously targeting multiple incretin receptors are of great interest, but balancing efficacy and tolerability has been a challenge,” commented Dr. Stig K. Hansen, Carmot’s Chief Executive Officer. “CT-868 is a dual incretin modulator with unique pharmacology and has demonstrated excellent efficacy and tolerability in pre-clinical models.”
The phase 1 study is designed to closely track safety and adverse effects with pharmacodynamic readouts.
Hansen believes CT-868 could provide better outcomes with fewer side effects for patients with type 2 diabetes and obesity.
The phase 1 study is a randomized, double-blind, placebo-controlled, dose escalation trial in overweight or obese healthy volunteers and patients with type 2 diabetes.
The first phase of the study will evaluate CT-868 in single ascending doses.
The second phase of the study will consist of multiple ascending doses over 14 days. The third phase will evaluate repeat dosing of CT-868 in patients with type 2 diabetes over a 28-day period and will include additional assessments of body weight and body fat composition.
Carmot Therapeutics is pioneering the discovery and development of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation.
Chemotype Evolution, Carmot’s proprietary technology, enables the rapid identification of novel drugs through an evolutionary discovery paradigm and has produced a pipeline of breakthrough therapeutics currently in pre-clinical development.
Source:
- Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes. Business Wire. 2018, December 19. Retrieved: https://www.businesswire.com/news/home/20181219005180/en